Advanced Bladder Urothelial Carcinoma

Oncology·MeSH: Urinary Bladder Neoplasms

Prevalence

61.0 / 100K

Incidence

18.0 / 100K/yr

11 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Avelumab	Merus N.V. (MRUS)
Avelumab	Royalty Pharma plc (RPRX)
Procarbazine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(6)

Drug	Company
Arginine hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Copanlisib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Defactinib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Eflornithine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Nilotinib Hydrochloride Monohydrate	ENANTA PHARMACEUTICALS INC (ENTA)
Propranolol Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(2)

Drug	Company
Avelumab	ENANTA PHARMACEUTICALS INC (ENTA)
Enfortumab Vedotin	Fulgent Genetics Inc. (FLGT)

BioSniper tracks 11 drugs in development for Advanced Bladder Urothelial Carcinoma across 4 companies.

There are 1 clinical trial targeting Advanced Bladder Urothelial Carcinoma tracked by BioSniper.

The estimated prevalence of Advanced Bladder Urothelial Carcinoma is approximately 61.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.